MedPath

WeExPAnd: PrEP Demonstration Project Among Women At Risk for HIV Infection - Preexposure Prophylaxis (PrEP)

Not Applicable
Completed
Conditions
HIV-infection/AIDS
Interventions
Behavioral: Cultural adaptation of a patient-provider communication tool
Registration Number
NCT04373551
Lead Sponsor
University of Alabama at Birmingham
Brief Summary

The objective of this application is to increase PrEP uptake among AA women vulnerable to HIV acquisition in the rural South, specifically those seeking care at Federally Qualified Healthcare Centers (FQHC) in rural Alabama.

The investigators will use a mixed-methods approach to adapt and pilot test a patient-provider communication tool from the CDC PrEP toolkit that focuses on the first three steps of the PrEP cascade (e.g., recognizing HIV risk, identifying as a PrEP candidate, and interested in PrEP) to increase PrEP uptake via referrals to local PrEP clinics.

Detailed Description

The investigators propose: (1) to explore the HIV risk perceptions of AA women with recent PrEP use, AA women who are candidates for PrEP, and providers and identify preferences around patient-provider communication about HIV risk and PrEP services that address the needs of AA women.

(2A) To systematically adapt a patient-provider communication tool to increase PrEP uptake at two FQHCs in rural Alabama, using an iterative implementation process; and (2B). To assess the feasibility, acceptability, and preliminary impact of the patient-provider communication intervention on PrEP uptake among AA women and their providers in a pilot pre-/post-intervention design.

As part of aim 2B), the investigators will also systematically document and evaluate reasons for declining a PrEP referral, reasons for incomplete referrals, reasons for failing to initiate PrEP after a successful referral, and ongoing PrEP use at 3 months and 12 months post PrEP initiation among our sample.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
67
Inclusion Criteria

Not provided

Read More
Exclusion Criteria

Not provided

Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Cultural adaptation of a patient-provider communication toolCultural adaptation of a patient-provider communication toolStrengthening of the PrEP care continuum by developing and testing an intervention designed to improve PrEP awareness, screening, engagement, retention, adherence, and persistence among individuals at substantial risk for HIV infection; developing and testing an intervention to reduce racial/disparities in PrEP uptake and use.
Primary Outcome Measures
NameTimeMethod
PrEP uptake changesbaseline, 3 months, and 12 months

To examine changes in PrEP uptake rates in the participating clinics comparing 3 years before and the year after the implementation of the protocol. Uptake will be calculated by the ratio of patients initiating PrEP to the number of eligible patients screened.

Intervention acceptabilityThrough study completion, an average of 12 months

All participants will be asked to consent to an in-depth, qualitative phone interview exploring their perceptions of the study, as well as an evaluation of the PrEP uptake intervention.

Intervention feasibility changesbaseline, 3 months, and 12 months

The following variable will be analyzed to determine feasibility: Number of participants screened, enrolled, and number who agreed to use PrEP and adhered to their prescribed regimen; reasons for declining enrollment, prematurely leaving the study, refusing a referral, failing to attend a PrEP clinic visit, and/or discontinuing PrEP. Recruitment and scheduling strategies, participant contact, and feasibility of administering instruments (e.g. assessment duration), will be documented and analyzed at each time frame.

Secondary Outcome Measures
NameTimeMethod
PrEP adherence3 months and 12 months

The AIDS Clinical Trials Group (ACTG) Adherence Questionnaire (i.e. Visual Analog Scale only) will be used to assess PrEP adherence, as is currently practice in the participating clinics. ACTG 's scores range from 0-4 with 4 indicating more adherence with 0 least adherent.

Clinic visit adherence changes3 months and 12 months

The following variable will be analyzed to determine adherence: PrEP visits adhered to, divided by visits scheduled. The change in retention to clinic care visits will be assessed at each assessment over 6-month intervals, which is in line with the 6 months post-intervention interval.

Trial Locations

Locations (1)

University of Alabama at Birmingham

🇺🇸

Birmingham, Alabama, United States

© Copyright 2025. All Rights Reserved by MedPath